Advanced Enzyme Technologies to Acquire Remaining 4.28% Stake in JC Biotech, Making It a Wholly Owned Subsidiary
Advanced Enzyme Technologies Ltd. has announced two strategic moves aimed at strengthening its subsidiary structure and expanding its presence in the pharmaceutical, nutrition and wellness businesses.
At its Board meeting held on August 8, 2026, the company approved the acquisition of the remaining 4.28% equity stake in JC Biotech Private Limited (JCB). The transaction will increase Advanced Enzyme Technologies’ ownership in JCB from 95.72% to 100%, making JC Biotech a wholly owned subsidiary.
The company has also approved an additional funding infusion of up to ₹20 million (₹2 crore) into its wholly owned subsidiary, Advanced Nutrazyme Private Limited (ANPL).
Advanced Enzyme to Take Full Control of JC Biotech
The key transaction announced by Advanced Enzyme Technologies is the acquisition of 886,544 equity shares, representing the remaining 4.28% stake in JC Biotech.
Advanced Enzyme already holds 95.72% of JCB. Following completion of the transaction, the company will own 100% of the subsidiary.
The acquisition consideration has been fixed at ₹90 per equity share, resulting in a total consideration of approximately ₹79.79 million (₹7.98 crore).
The transaction is expected to be completed by September 30, 2026, according to the company’s disclosure.
JC Biotech: A Pharmaceutical and Biopharma Business
JC Biotech was incorporated on December 31, 1991 and was acquired by Advanced Enzyme Technologies in 2016.
The company is engaged in the manufacturing and sale of biopharmaceutical products through aerobic fermentation and operates in India.
JCB has also demonstrated growth in its revenue base over the past three financial years:
| Financial Year | JC Biotech Turnover |
|---|---|
| FY26 | ₹72.8 crore |
| FY25 | ₹60.0 crore |
| FY24 | ₹62.7 crore |
The FY26 turnover of ₹72.8 crore highlights the scale of the business being brought fully under Advanced Enzyme Technologies’ ownership.
Why Is Advanced Enzyme Buying the Remaining Stake?
According to the company, the primary objective of the transaction is to make JC Biotech a wholly owned subsidiary and optimize synergies across business operations at the consolidated level.
Moving from 95.72% ownership to 100% may appear relatively small in percentage terms, but full ownership can simplify the group’s corporate structure and allow the parent company to capture the entire economic interest in the subsidiary.
It can also provide greater flexibility in managing the subsidiary’s operations, capital allocation and future growth plans.
The acquisition is being made through cash consideration, with the shares being purchased at ₹90 each.
₹2 Crore Funding Infusion into Advanced Nutrazyme
Alongside the JCB acquisition, the Board approved an additional investment of up to ₹20 million (₹2 crore) in Advanced Nutrazyme Private Limited.
The funds may be provided in one or more tranches through:
- Equity investment, or
- Inter-corporate deposit
Advanced Nutrazyme is already a wholly owned subsidiary of Advanced Enzyme Technologies.
The company said the funds will be used for business and general corporate purposes.
Advanced Nutrazyme’s Focus on Nutrition and Wellness
Advanced Nutrazyme was incorporated on July 4, 2025 and is engaged in the marketing and sale of nutraceutical products.
The subsidiary is part of Advanced Enzyme’s broader strategy around its Nutrition and Wellness product portfolio.
While the business is still at an early stage, its additional funding indicates that the company is looking to build the subsidiary’s operations and distribution capabilities.
ANPL reported revenue of only ₹0.02 million (₹20,000) in FY26, reflecting its relatively early stage of operations.
The company expects the additional capital to support the development of this business.
Acquisition vs. Investment: Key Details
| Particular | JC Biotech | Advanced Nutrazyme |
| Transaction | Acquisition of remaining stake | Additional fund infusion |
| Current ownership | 95.72% | 100% |
| Post-transaction ownership | 100% | 100% |
| Business | Biopharmaceuticals | Nutrition & Wellness |
| Transaction value | ₹7.98 crore | Up to ₹2 crore |
| Consideration | Cash | Equity / Inter-corporate deposit |
| Key objective | Create wholly owned subsidiary and optimize synergies | Fund business and corporate requirements |
| Expected completion | September 30, 2026 | December 31, 2027 |
JC Biotech Adds a More Established Business
One important difference between the two subsidiaries is their current scale.
JC Biotech is an established operating business with FY26 turnover of ₹72.8 crore, compared with Advanced Nutrazyme, which generated only ₹0.02 million in FY26.
Therefore, the JCB transaction is primarily about consolidating ownership of an existing operating business, while the ANPL investment is more of a growth and expansion initiative.
The two transactions therefore serve different strategic purposes within Advanced Enzyme’s portfolio.
Advanced Enzyme Also Announces ₹69.7 Crore Buyback
The acquisition announcement came alongside another major capital-allocation decision.
Advanced Enzyme Technologies’ Board approved a share buyback of up to ₹697 million (₹69.7 crore) at a maximum price of ₹500 per equity share through the open-market route.
At the maximum buyback price, the company could repurchase up to 1.394 million shares, representing approximately 1.24% of its existing paid-up equity share capital.
The buyback will be available to shareholders other than the promoters, promoter group and persons in control of the company.
At the maximum buyback scenario, the promoter and promoter group holding is indicated to rise from 43.24% to 43.79%, while public shareholding would move from 56.76% to 56.21%, assuming the maximum number of shares are bought back.
The company said the formal public announcement containing the buyback process and timelines will be released separately.
Q1 FY27 Financial Performance
The strategic announcements were made along with the company’s unaudited financial results for the quarter ended June 30, 2026.
On a consolidated basis, Advanced Enzyme Technologies reported:
| Particular | Q1 FY27 |
| Revenue from Operations | ₹203.37 crore |
| Total Income | ₹202.81 crore |
| Profit Before Tax | ₹53.53 crore |
| Net Profit | ₹38.59 crore |
| EPS | ₹3.31 |
For comparison, consolidated net profit was ₹45.25 crore in Q1 FY26, while revenue from operations stood at ₹203.37 crore compared with ₹189.79 crore in the year-ago quarter.
On a standalone basis, the company reported revenue from operations of approximately ₹115.86 crore and net profit of ₹22.35 crore for Q1 FY27.
What the Moves Mean for Investors
Advanced Enzyme Technologies’ latest announcements highlight three distinct areas of its strategy: greater ownership, investment in new growth businesses and shareholder returns.
The acquisition of the remaining JCB stake gives the company complete ownership of a biopharmaceutical business that generated ₹72.8 crore of revenue in FY26.
At the same time, the ₹2 crore funding commitment to Advanced Nutrazyme provides capital for developing the company’s newer nutrition and wellness business.
The ₹69.7 crore buyback, meanwhile, represents a significant capital-return initiative for shareholders.
Taken together, these decisions indicate that Advanced Enzyme is attempting to balance business expansion with capital allocation to shareholders.
Advanced Enzyme Technologies’ decision to acquire the remaining 4.28% stake in JC Biotech is strategically important because it will convert an existing subsidiary into a 100% owned business.
The ₹7.98 crore transaction is relatively modest compared with the group’s overall operations, but full ownership could help simplify the structure and improve operational synergies.
The additional ₹2 crore funding for Advanced Nutrazyme signals continued investment in the company’s nutrition and wellness opportunity, while the ₹69.7 crore buyback demonstrates a parallel focus on shareholder returns.
Investors will now be watching how effectively Advanced Enzyme integrates the fully owned JCB business, scales Advanced Nutrazyme and executes its broader growth strategy in the coming quarters.
This article is based on the company’s stock-exchange disclosure dated August 8, 2026. It is for informational purposes only and should not be considered investment advice.